What can we expect from Geron Corporation (Gern) stock?
Given the current horizontal trend, you can expect Geron Corporation stock with a 90% probability to be traded between $1.30 and $1.75 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top.
Does Gern stock pay a dividend?
Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price. GERN is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased.
How does Gern compare to other healthcare stocks?
Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to www.geron.com. GERN's price/sales ratio is 1156.5; this is 30334.21% higher than that of the median Healthcare stock.
What do large amount of stocks bought compared to stock sold?
The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside. In some cases larger purchases can be explained by due date for stock options. The predicted opening price is based on yesterday's movements between high, low, and the closing price.
See more
Is Gern a good stock to invest?
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Is Geron a good investment?
(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 307.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 18.55%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.52%. Geron's revenue in 2022 is $1,379,000.
Who owns Gern stock?
Institutional investors purchased a net $1.3 million shares of GERN during the quarter ended June 2019 and now own 30.74% of the total shares outstanding....Top 10 Owners of Geron Corp.StockholderBlackRock Fund AdvisorsStake5.91%Shares owned22,284,940Total value ($)31,421,765Shares bought / sold-451,1109 more columns
What does Geron make?
Corporate Profile. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
What does Geron Corporation do?
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Who owns Geron?
Geron is not owned by hedge funds. The company's largest shareholder is RA Capital Management, L.P., with ownership of 9.4%. For context, the second largest shareholder holds about 7.9% of the shares outstanding, followed by an ownership of 4.8% by the third-largest shareholder.
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4)
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4)
Geron to Present at the H.C. Wainwright BioConnect Conference
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron to Present at the H.C. Wainwright BioConnect Conference
Geron Reports Presentations at American Society of Hematology Annual Meeting
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Reports Presentations at American Society of Hematology Annual Meeting
Geron Announces Appointment of Chief Business Officer
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Announces Appointment of Chief Business Officer
Geron to Present at the Stifel 2021 Virtual Healthcare Conference
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies...
Geron Presents Investor Event Highlights
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies...
Signals & Forecast
There are mixed signals in the stock today. The Geron Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
Geron Corporation finds support from accumulated volume at $1.02 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Geron Corporation stock A Buy?
Geron Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Geron Corporation
In the last 100 trades there were 19.65 million shares bought and 285.64 thousand shares sold. The last trade was done 8 days ago by Bloom Olivia Kyusuk who bough 750 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Geron Corporation
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Is Geron a phase 2 company?
FOSTER CITY, Calif., Jun 17, 2021--Geron Corporation (Nasdaq: GERN), a late-s tage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, "Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis." The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as
Is Geron stock up?
Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinical Oncology. The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as positive biomarker and bone marrow fibrosis assessments, in heavily pre-treated patients. As stated in the paper, IMbark tested two imetelstat doses, and
What is Geron's Zacks rank?
Currently, Geron is a Zacks Rank #3 (Hold) in Medical - Biomedical and Genetics industry that ranks in the Bottom 13% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while two analysts have revised their estimates downward.
When did Zacks discover earnings estimate revisions?
In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. Learn More.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Geron shares, but what is the fundamental picture for the company? Currently, Geron is a Zacks Rank #3 (Hold) in Medical - Biomedical and Genetics industry that ranks in the Bottom 13% of our Zacks Industry Rank.
Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.
